Gastroenteropancreatic neuroendocrine tumors and the NETTER-1 trial

Martyn Caplin speaks to Senior Editor: , Roshaine Wijayatunga. Martyn is a professor of gastroenterology and GI neuroendocrinology at the Neuroendocrine Tumour Unit at the Royal Free London and University College London. He is immediate past-Chairman of the European Neuroendocrine Tumor Society. He...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of endocrine oncology Vol. 4; no. 4; pp. 155 - 157
Main Author Caplin, Martyn
Format Journal Article
LanguageEnglish
Published London Future Medicine Ltd 01.11.2017
Subjects
Biopsy
Caplin
Clinical trials
Disease
gastroenteropancreatic neuroendocrine
GEP-NETs
Hospitals
lutathera
NETTER-1
Neuroendocrine tumors
Patients
Survival analysis
tumor NET
United Kingdom > UK
Online AccessGet full text

Cover

More Information
Summary:Martyn Caplin speaks to Senior Editor: , Roshaine Wijayatunga. Martyn is a professor of gastroenterology and GI neuroendocrinology at the Neuroendocrine Tumour Unit at the Royal Free London and University College London. He is immediate past-Chairman of the European Neuroendocrine Tumor Society. He is founder and past-Chairman of the UK and Ireland Neuroendocrine Tumor Society as well as NCRI Neuroendocrine Tumor Group. He received a lifetime achievement award in recognition of his clinical leadership and research in the field of NETs. Former clinical lead for 'NHS Evidence' for gastroenterology and liver diseases. He has published over 200 peer review papers, written multiple book chapters and co-authored two books. He regularly lectures both nationally and internationally.
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Interview-1
ISSN:2045-0869
2045-0877
DOI:10.2217/ije-2017-0023